Eric Roeland
@ericroeland.bsky.social
#PallOnc MD improving the lives of people with cancer through #SymptomScience #ClinicalTrials #ASCOGuidelines | #CancerCachexia #irAE #PalliativeCare #SuppOnc | Member #OncSky #ASCO #ASPIRE #AAHPM #MASCC | skier, nature lover | views are mine
Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....
September 1, 2025 at 6:50 PM
Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....
🌟 Got questions about #irAEs? 🤔 What about tumor deposits in the lung or liver—do they heighten the risk? Recent retrospective data from hospitalized patients suggests an association 🚨 jitc.bmj.com/content/13/5... #ASPIRE @aspire-cop.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social
May 20, 2025 at 11:52 PM
🌟 Got questions about #irAEs? 🤔 What about tumor deposits in the lung or liver—do they heighten the risk? Recent retrospective data from hospitalized patients suggests an association 🚨 jitc.bmj.com/content/13/5... #ASPIRE @aspire-cop.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social
And physical function
May 16, 2025 at 12:06 AM
And physical function
#SymptomScience pilot study showing feasibility of low-intensity vibration to reduce #CIPN and improve physical function in cancer survivors @advocatecollab.bsky.social @ascocancer.bsky.social @cancercaremascc.bsky.social @pallonccop.bsky.social @ryannipp.bsky.social ascopubs.org/doi/10.1200/...
May 16, 2025 at 12:02 AM
#SymptomScience pilot study showing feasibility of low-intensity vibration to reduce #CIPN and improve physical function in cancer survivors @advocatecollab.bsky.social @ascocancer.bsky.social @cancercaremascc.bsky.social @pallonccop.bsky.social @ryannipp.bsky.social ascopubs.org/doi/10.1200/...
Adding to growing evidence of #AI -based CT scan muscle analysis in cancer. Pts with mCRC receiving 1L FOLFOX or FOLFIRI with low skeletal muscle index had higher rates of ≥G3 neutropenia. journals.sagepub.com/eprint/RSAKM... #CancerCachexia @ryannipp.bsky.social @pallonccop.bsky.social
May 6, 2025 at 1:18 PM
Adding to growing evidence of #AI -based CT scan muscle analysis in cancer. Pts with mCRC receiving 1L FOLFOX or FOLFIRI with low skeletal muscle index had higher rates of ≥G3 neutropenia. journals.sagepub.com/eprint/RSAKM... #CancerCachexia @ryannipp.bsky.social @pallonccop.bsky.social
Thankful @nejm.org #CancerCachexia ponsegromab study highlighted as NEJM Notable Articles of 2024 #SymptomScience www.nejm.org/doi/full/10.... @ascocancer.bsky.social @cancercachexia.bsky.social @pallonccop.bsky.social @cancercaremascc.bsky.social @ohsuknight.bsky.social @drr-dunne.bsky.social
December 19, 2024 at 2:06 PM
Thankful @nejm.org #CancerCachexia ponsegromab study highlighted as NEJM Notable Articles of 2024 #SymptomScience www.nejm.org/doi/full/10.... @ascocancer.bsky.social @cancercachexia.bsky.social @pallonccop.bsky.social @cancercaremascc.bsky.social @ohsuknight.bsky.social @drr-dunne.bsky.social
